SAV

Análisis de la acción SAV (SAV)

$24.750

+0.020 (+0.08%)Al cierre

Loading chart…
Máximo
24.800
Apertura
24.800
Precio medio ponderado por volumen
24.75
Volumen
1.58K
Capitalización
—
Mínimo
24.688
Importe
39.17K
EV/EBITDA, TTM
—

Análisis de IA of SAV (SAV)

Comprar

Cassava Sciences Inc (SAVA) appears to be a good buy right now, especially considering its current price of 2.38, which is well below its 52-week high of 3.45. The recent closure of the DOJ investigation and the company's strategic rebranding to Filana Therapeutics are positive catalysts that could enhance investor confidence. Additionally, the RSI is at 66.474, indicating strong momentum, while the stock has seen a 16.10% increase over the last 20 days, suggesting a bullish trend. However, the main risk is the company's negative net income, which was -44224000 in Q2 2025, highlighting ongoing financial challenges that investors should monitor closely.

Preguntas frecuentes sobre SAV, respondidas por Alphio AI

Cassava Sciences Inc (SAVA) appears to be a good buy right now, especially considering its current price of 2.38, which is well below its 52-week high of 3.45. The recent closure of the DOJ investigation and the company's strategic rebranding to Filana Therapeutics are positive catalysts that could enhance investor confidence. Additionally, the RSI is at 66.474, indicating strong momentum, while the stock has seen a 16.10% increase over the last 20 days, suggesting a bullish trend. However, the main risk is the company's negative net income, which was -44224000 in Q2 2025, highlighting ongoing financial challenges that investors should monitor closely.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar